Duration of High-Dose Interferon Alfa-2b Regimen for Resected High-Risk Melanoma

被引：2

作者：

Agarwala, Sanjiv S. ^{[1
,2
]}

Gray, Robert J. ^{[3
,4
]}

Wong, Michael K. K. ^{[5
]}

机构：

[1] Univ Penn, Philadelphia, PA 19104 USA

[2] St Lukes Canc Ctr, Bethlehem, PA USA

[3] Dana Farber Canc Inst, Boston, MA 02115 USA

[4] Harvard Univ, Boston, MA 02115 USA

[5] GU Clin Roswell Pk Canc Inst, Buffalo, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 25期

关键词：

ADJUVANT THERAPY; TRIAL;

D O I：

10.1200/JCO.2009.23.0334

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

下载

页码：E82 / E83

页数：2

共 50 条

[31] LONG-TERM ADJUVANT THERAPY OF HIGH-RISK MALIGNANT-MELANOMA WITH RECOMBINANT INTERFERON ALFA-2B
KOKOSCHKA, EM
TRAUTINGER, F
MISCKSCHE, M
KOKOSCHKA, R
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1989, 93 (04) : 560 - 560
[32] Use of adjuvant interferon alfa-2b or ipilimumab 10 mg/kg for high-risk patients with melanoma, and associated adverse events and duration of therapy
Tarhini, Ahmad
Gupte-Singh, Komal
You, Min
Gupta, Amit
Kim, Le Trong
Rao, Sumati
CANCER RESEARCH, 2018, 78 (13)
[33] Interferon alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon alfa-2b treatment
Bramlette, Tracy B.
Lawson, David H.
Washington, Carl V.
Veledar, Emir
Johns, Barry R.
Brisman, Stacey F.
Abramova, Liana
Chen, Suephy C.
DERMATOLOGIC SURGERY, 2007, 33 (01) : 11 - 16
[34] HIGH DOSE IFN ALFA-2B ADJUVANT THERAPY OF HIGH-RISK RESECTED CUTANEOUS MELANOMA. RESULTS AFTER 31 MONTHS MEDIAN FOLLOW-UP
Muggiano, A.
Mulas, C.
Fiori, B.
Liciardi, G.
Pintus, M.
Tanca, L.
Tedde, A.
Turno, R.
Desogus, A.
ANNALS OF ONCOLOGY, 2004, 15 : 85 - 86
[35] Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III–IV melanoma in phase III trial E1609
Laurie E. McLouth
Yue Zheng
Stephanie Smith
F. Stephen Hodi
Uma N. Rao
Gary I. Cohen
Thomas T. Amatruda
Shaker R. Dakhil
Brendan D. Curti
Ibrahim Nakhoul
Sreenivasa R. Chandana
Charles L. Bane
David E. Marinier
Sandra J. Lee
Vernon K. Sondak
John M. Kirkwood
Ahmad A. Tarhini
Lynne I. Wagner
Quality of Life Research, 2023, 32 : 183 - 196
[36] Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697)
Agarwala, S. S.
Lee, S. J.
Flaherty, L. E.
Smylie, M.
Kefford, R. F.
Carson, W. E.
Cohen, G.
Kirkwood, J. M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[37] Present status and future prospects for adjuvant therapy of melanoma: Time to build upon the foundation of high-dose interferon alfa-2b
Moschos, SJ
Kirkwood, JM
Konstantinopoulos, PA
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 11 - 14
[38] Adjuvant interferon in high-risk melanoma: The AIM HIGH study-United Kingdom Coordinating Committee on cancer research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma
Hancock, BW
Wheatley, K
Harris, S
Ives, N
Harrison, G
Horsman, JM
Middleton, MR
Thatcher, N
Lorigan, PC
Marsden, JR
Burrows, L
Gore, M
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) : 53 - 61
[39] Lymphocyte subpopulations and interleukin levels in high-risk melanoma patients treated with high-dose interferon A-2B
Gogas, H
Paterakis, G
Frangia, K
Bafaloukos, D
Pectasides, D
Kalofonos, HP
Loukopoulos, D
Stavropoulou-Giokas, C
Ioannovich, J
Mihm, MC
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06): : 591 - 596
[40] Adjuvant therapy with high-dose interferon α2b in patients with high-risk stage IIB/III melanoma
Kirkwood, John M.
Tarhini, Ahmad A.
Moschos, Stergios J.
Panelli, Monica C.
NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (01): : 2 - 3

← 1 2 3 4 5 →